Connection
Janet Rader to Infusions, Intravenous
This is a "connection" page, showing publications Janet Rader has written about Infusions, Intravenous.
|
|
Connection Strength |
|
|
|
|
|
0.098 |
|
|
|
-
Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003 Nov; 91(2):318-25.
Score: 0.055
-
Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 Nov; 103(2):637-41.
Score: 0.017
-
Armstrong DK, Blessing JA, Rader J, Sorosky JI. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest New Drugs. 2003 Nov; 21(4):453-7.
Score: 0.014
-
Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Ann Oncol. 2002 Nov; 13(11):1819-25.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|